Omeros (OMER)

• Market cap: $512M
• 1 day: -2.08%
• 5 days: -2.46%
• 1 month: 83.41%
• 3 months: 95.32%
• 6 months: 2.31%
• Year to date: -23.58%
• 1 year: 78.2%
• 5 years: -25.84%
• 10 years: -39.98%
• Sector: Healthcare
• Industry: Biotechnology

About: Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Employees: 202